f Detection of Inflammatory Bowel Disease Activity by Non-invasive Biomarkers: Still a Long Way Ahead

References

1. Tavakoli P. Vollmer-Conna U. Hadzi-Pavlovic D. Grimm M.C. A review of inflammatory bowel disease: A model of microbial, immune and neuropsychological integration. Public Health Rev. 2021 42 1603990 10.3389/phrs.2021.1603990 34692176
   [Google Scholar]
2. Caron B. Honap S. Peyrin-Biroulet L. Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies. J. Crohn’s Colitis 2024 18 Suppl. 2 ii3 ii15 10.1093/ecco‑jcc/jjae082 39475082
   [Google Scholar]
3. Odze R.D. A contemporary and critical appraisal of ‘indeterminate colitis’. Mod. Pathol. 2015 28 Suppl. 1 S30 S46 10.1038/modpathol.2014.131 25560598
   [Google Scholar]
4. Rutkowski K. Udrycka K. Włodarczyk B. Małecka-Wojciesko E. Microscopic colitis: An underestimated disease of growing importance. J. Clin. Med. 2024 13 19 5683 10.3390/jcm13195683 39407743
   [Google Scholar]
5. Piovani D. Danese S. Peyrin-Biroulet L. Nikolopoulos G.K. Lytras T. Bonovas S. Environmental risk factors for inflammatory bowel diseases: An umbrella review of meta-analyses. Gastroenterology 2019 157 3 647 659.e4 10.1053/j.gastro.2019.04.016 31014995
   [Google Scholar]
6. Torres J. Gomes C. Jensen C.B. Agrawal M. Ribeiro-Mourão F. Jess T. Colombel J.F. Allin K.H. Burisch J. Risk factors for developing inflammatory bowel disease within and across families with a family history of IBD. J. Crohn’s Colitis 2023 17 1 30 36 10.1093/ecco‑jcc/jjac111 35943898
   [Google Scholar]
7. Bretto E. Frara S. Armandi A. Caviglia G.P. Saracco G.M. Bugianesi E. Pitoni D. Ribaldone D.G. Helicobacter pylori in inflammatory bowel diseases: Active protagonist or innocent bystander? Antibiotics 2024 13 3 267 10.3390/antibiotics13030267 38534702
   [Google Scholar]
8. McDowell C. Farooq U. Haseeb M. Inflamm. Bowel Dis. Treasure Island (FL): StatPearls 2025
   [Google Scholar]
9. Ranasinghe I. R. Tian C. Hsu R. Crohn Disease. Treasure Island (FL): StatPearls 2025
   [Google Scholar]
10. Lynch W. D. Hsu R. Ulcerative Colitis. Treasure Island (FL): StatPearls 2025
    [Google Scholar]
11. Hunter Gibble T. Sweeney C. Wolin D. McSorley D. Wang J. Moses R. Dubinsky M. Evaluation of the symptoms and clinical characteristics of crohn’s disease and ulcerative colitis that affect healthcare providers’ treatment choices. Crohns Colitis 360 2024 6 4 otae053 10.1093/crocol/otae053 39403225
    [Google Scholar]
12. Liu D. Saikam V. Skrada K.A. Merlin D. Iyer S.S. Inflammatory bowel disease biomarkers. Med. Res. Rev. 2022 42 5 1856 1887 10.1002/med.21893 35603998
    [Google Scholar]
13. Vrabie R. Kane S. Noninvasive markers of disease activity in inflammatory bowel disease. Gastroenterol. Hepatol. 2014 10 9 576 584 27551251
    [Google Scholar]
14. Honap S. Jairath V. Danese S. Peyrin-Biroulet L. Navigating the complexities of drug development for inflammatory bowel disease. Nat. Rev. Drug Discov. 2024 23 7 546 562 10.1038/s41573‑024‑00953‑0 38778181
    [Google Scholar]
15. Fiorucci S. Marchianò S. Urbani G. Di Giorgio C. Distrutti E. Zampella A. Biagioli M. Immunology of bile acids regulated receptors. Prog. Lipid Res. 2024 95 101291 10.1016/j.plipres.2024.101291 39122016
    [Google Scholar]
16. Biagioli M. Marchianò S. Carino A. Di Giorgio C. Santucci L. Distrutti E. Fiorucci S. Bile acids activated receptors in inflammatory bowel disease. Cells 2021 10 6 1281 10.3390/cells10061281 34064187
    [Google Scholar]
17. Danese S. Panés J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 2014 147 5 981 989 10.1053/j.gastro.2014.08.044 25220794
    [Google Scholar]
18. Mencarelli A. Cipriani S. Francisci D. Santucci L. Baldelli F. Distrutti E. Fiorucci S. Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. Sci. Rep. 2016 6 1 30802 10.1038/srep30802 27492684
    [Google Scholar]
19. Biagioli M. Di Giorgio C. Morretta E. Bellini R. Massa C. Urbani G. Bordoni M. Marchianò S. Lachi G. Sepe V. Monti M.C. Distrutti E. Zampella A. Fiorucci S. Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases. Pharmacol. Res. 2024 208 107403 10.1016/j.phrs.2024.107403 39265668
    [Google Scholar]
20. Mohanty I. Allaband C. Mannochio-Russo H. El Abiead Y. Hagey L.R. Knight R. Dorrestein P.C. The changing metabolic landscape of bile acids – keys to metabolism and immune regulation. Nat. Rev. Gastroenterol. Hepatol. 2024 21 7 493 516 10.1038/s41575‑024‑00914‑3 38575682
    [Google Scholar]
21. Gevers D. Kugathasan S. Denson L.A. Vázquez-Baeza Y. Van Treuren W. Ren B. Schwager E. Knights D. Song S.J. Yassour M. Morgan X.C. Kostic A.D. Luo C. González A. McDonald D. Haberman Y. Walters T. Baker S. Rosh J. Stephens M. Heyman M. Markowitz J. Baldassano R. Griffiths A. Sylvester F. Mack D. Kim S. Crandall W. Hyams J. Huttenhower C. Knight R. Xavier R.J. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014 15 3 382 392 10.1016/j.chom.2014.02.005 24629344
    [Google Scholar]
22. Iacucci M. Santacroce G. Maeda Y. Ghosh S. AI-driven personalized medicine: Transforming clinical practice in inflammatory bowel disease. Gastroenterology 2025 5085 25 00494 00499 10.1053/j.gastro.2025.03.005 40074186
    [Google Scholar]